A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
Latest Information Update: 10 Feb 2022
At a glance
- Drugs Algenpantucel-L (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Registrational; Therapeutic Use
- Acronyms PILLAR
- Sponsors NewLink Genetics Corporation
- 01 Jan 2022 Primary endpoint (Overall Survival) has not been met as per results published in the Annals of Surgery
- 01 Jan 2022 Results published in the Annals of Surgery
- 21 Feb 2019 Status changed from active, no longer recruiting to discontinued.